Breaking News, Collaborations & Alliances

GT Biopharma and Cytovance Biologics Expand Partnership

Cytovance will be the exclusive GMP manufacture for three of the company's TriKE therapeutic product candidates.

By: Contract Pharma

Contract Pharma Staff

GT Biopharma, a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager (TriKE), entered into a partnership with Cytovance Biologics, a U.S.-based contract development and manufacturing organization (CDMO) and a subsidiary of the Shenzhen Hepalink Pharmaceutical Group.   Cytovance will be the exclusive GMP manufacture for three of the company’s TriKE therapeutic product candidates. Cytovance will manufacture TriKE in accordance with GMP usin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters